High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction

Autores
Olea, Fernanda Daniela; Vera Janavel, Gustavo; De Lorenzi, Andrea; Cuniberti, Luis Alberto; Yannarelli, Gustavo Gabriel; Cabeza Meckert, Patricia; Cearras, Martín; Laguens, Rubén; Crottogini, Alberto Jose
Año de publicación
2006
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
High-dose erythropoietin has been claimed to be cardioprotective in experimental acute myocardial infarction. In large mammals, however, results are controversial and long-term follow-up data are lacking. We thus assessed the long-term effects of high-dose erythropoietin on left ventricular infarct size and function in an ovine model of reperfused myocardial infarction. After 90 minutes of coronary occlusion followed by reperfusion, sheep received recombinant human erythropoietin (rhEPO) 3000 units/kg on 3 consecutive days (rhEPO group, n=7) or vehicle (placebo group, n=6). Ten weeks later, ventricular function was assessed by echocardiography and catheterization. Infarct size, evaluated as percent fibrotic myocardium (morphometry) and by hydroxyproline quantification, was similar in both groups (morphometry: rhEPO: 22.1 +/- 5.5%, placebo: 18.1 +/- 3.3%, P not significant; hydroxyproline: rhEPO: 6.6 +/- 1.3 microg/mg wet weight, placebo: 7.1 +/- 0.9 microg/mg, P not significant). Ventricular function was diminished in the rhEPO group, as indicated by lower septal wall thickening at the infarct border zone (rhEPO: -1.9 +/- 16.4%, placebo: 20.5 +/- 17%, P<0.04), higher end systolic volume (rhEPO: 47 +/- 14.3 mL, placebo: 32.6 +/- 7.3 mL, P<0.05), and higher end diastolic pressure (rhEPO: 17 +/- 6.5 mm Hg, placebo: 10.1 +/- 2.8 mm Hg, P<0.03). In the rhEPO group, left ventricular endocardial area was larger, suggesting dilatation. High-dose erythropoietin has no cardioprotective effects in sheep with reperfused myocardial infarction.
Fil: Olea, Fernanda Daniela. Fundación Favaloro; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vera Janavel, Gustavo. No especifíca;
Fil: De Lorenzi, Andrea. Fundación Favaloro; Argentina
Fil: Cuniberti, Luis Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Favaloro; Argentina
Fil: Yannarelli, Gustavo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Favaloro; Argentina
Fil: Cabeza Meckert, Patricia. Fundación Favaloro; Argentina
Fil: Cearras, Martín. No especifíca;
Fil: Laguens, Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Crottogini, Alberto Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
sheep
erythropoietin
myocardial infarction
reperfusion
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/245050
Acceder
id CONICETDig_f25d4168f649405c6a0b38474c423e9a
oai_identifier_str oai:ri.conicet.gov.ar:11336/245050
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial InfarctionOlea, Fernanda DanielaVera Janavel, GustavoDe Lorenzi, AndreaCuniberti, Luis AlbertoYannarelli, Gustavo GabrielCabeza Meckert, PatriciaCearras, MartínLaguens, RubénCrottogini, Alberto Josesheeperythropoietinmyocardial infarctionreperfusionhttps://purl.org/becyt/ford/3.5https://purl.org/becyt/ford/3High-dose erythropoietin has been claimed to be cardioprotective in experimental acute myocardial infarction. In large mammals, however, results are controversial and long-term follow-up data are lacking. We thus assessed the long-term effects of high-dose erythropoietin on left ventricular infarct size and function in an ovine model of reperfused myocardial infarction. After 90 minutes of coronary occlusion followed by reperfusion, sheep received recombinant human erythropoietin (rhEPO) 3000 units/kg on 3 consecutive days (rhEPO group, n=7) or vehicle (placebo group, n=6). Ten weeks later, ventricular function was assessed by echocardiography and catheterization. Infarct size, evaluated as percent fibrotic myocardium (morphometry) and by hydroxyproline quantification, was similar in both groups (morphometry: rhEPO: 22.1 +/- 5.5%, placebo: 18.1 +/- 3.3%, P not significant; hydroxyproline: rhEPO: 6.6 +/- 1.3 microg/mg wet weight, placebo: 7.1 +/- 0.9 microg/mg, P not significant). Ventricular function was diminished in the rhEPO group, as indicated by lower septal wall thickening at the infarct border zone (rhEPO: -1.9 +/- 16.4%, placebo: 20.5 +/- 17%, P<0.04), higher end systolic volume (rhEPO: 47 +/- 14.3 mL, placebo: 32.6 +/- 7.3 mL, P<0.05), and higher end diastolic pressure (rhEPO: 17 +/- 6.5 mm Hg, placebo: 10.1 +/- 2.8 mm Hg, P<0.03). In the rhEPO group, left ventricular endocardial area was larger, suggesting dilatation. High-dose erythropoietin has no cardioprotective effects in sheep with reperfused myocardial infarction.Fil: Olea, Fernanda Daniela. Fundación Favaloro; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Vera Janavel, Gustavo. No especifíca;Fil: De Lorenzi, Andrea. Fundación Favaloro; ArgentinaFil: Cuniberti, Luis Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Favaloro; ArgentinaFil: Yannarelli, Gustavo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Favaloro; ArgentinaFil: Cabeza Meckert, Patricia. Fundación Favaloro; ArgentinaFil: Cearras, Martín. No especifíca;Fil: Laguens, Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Crottogini, Alberto Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaLippincott Williams2006-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/245050Olea, Fernanda Daniela; Vera Janavel, Gustavo; De Lorenzi, Andrea; Cuniberti, Luis Alberto; Yannarelli, Gustavo Gabriel; et al.; High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction; Lippincott Williams; Journal of Cardiovascular Pharmacology; 47; 6; 6-2006; 736-7410160-2446CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1097/01.fjc.0000211766.59636.0dinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:07:49Zoai:ri.conicet.gov.ar:11336/245050instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:07:49.86CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
title High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
spellingShingle High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
Olea, Fernanda Daniela
sheep
erythropoietin
myocardial infarction
reperfusion
title_short High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
title_full High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
title_fullStr High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
title_full_unstemmed High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
title_sort High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction
dc.creator.none.fl_str_mv Olea, Fernanda Daniela
Vera Janavel, Gustavo
De Lorenzi, Andrea
Cuniberti, Luis Alberto
Yannarelli, Gustavo Gabriel
Cabeza Meckert, Patricia
Cearras, Martín
Laguens, Rubén
Crottogini, Alberto Jose
author Olea, Fernanda Daniela
author_facet Olea, Fernanda Daniela
Vera Janavel, Gustavo
De Lorenzi, Andrea
Cuniberti, Luis Alberto
Yannarelli, Gustavo Gabriel
Cabeza Meckert, Patricia
Cearras, Martín
Laguens, Rubén
Crottogini, Alberto Jose
author_role author
author2 Vera Janavel, Gustavo
De Lorenzi, Andrea
Cuniberti, Luis Alberto
Yannarelli, Gustavo Gabriel
Cabeza Meckert, Patricia
Cearras, Martín
Laguens, Rubén
Crottogini, Alberto Jose
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv sheep
erythropoietin
myocardial infarction
reperfusion
topic sheep
erythropoietin
myocardial infarction
reperfusion
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.5
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv High-dose erythropoietin has been claimed to be cardioprotective in experimental acute myocardial infarction. In large mammals, however, results are controversial and long-term follow-up data are lacking. We thus assessed the long-term effects of high-dose erythropoietin on left ventricular infarct size and function in an ovine model of reperfused myocardial infarction. After 90 minutes of coronary occlusion followed by reperfusion, sheep received recombinant human erythropoietin (rhEPO) 3000 units/kg on 3 consecutive days (rhEPO group, n=7) or vehicle (placebo group, n=6). Ten weeks later, ventricular function was assessed by echocardiography and catheterization. Infarct size, evaluated as percent fibrotic myocardium (morphometry) and by hydroxyproline quantification, was similar in both groups (morphometry: rhEPO: 22.1 +/- 5.5%, placebo: 18.1 +/- 3.3%, P not significant; hydroxyproline: rhEPO: 6.6 +/- 1.3 microg/mg wet weight, placebo: 7.1 +/- 0.9 microg/mg, P not significant). Ventricular function was diminished in the rhEPO group, as indicated by lower septal wall thickening at the infarct border zone (rhEPO: -1.9 +/- 16.4%, placebo: 20.5 +/- 17%, P<0.04), higher end systolic volume (rhEPO: 47 +/- 14.3 mL, placebo: 32.6 +/- 7.3 mL, P<0.05), and higher end diastolic pressure (rhEPO: 17 +/- 6.5 mm Hg, placebo: 10.1 +/- 2.8 mm Hg, P<0.03). In the rhEPO group, left ventricular endocardial area was larger, suggesting dilatation. High-dose erythropoietin has no cardioprotective effects in sheep with reperfused myocardial infarction.
Fil: Olea, Fernanda Daniela. Fundación Favaloro; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vera Janavel, Gustavo. No especifíca;
Fil: De Lorenzi, Andrea. Fundación Favaloro; Argentina
Fil: Cuniberti, Luis Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Favaloro; Argentina
Fil: Yannarelli, Gustavo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Favaloro; Argentina
Fil: Cabeza Meckert, Patricia. Fundación Favaloro; Argentina
Fil: Cearras, Martín. No especifíca;
Fil: Laguens, Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Crottogini, Alberto Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description High-dose erythropoietin has been claimed to be cardioprotective in experimental acute myocardial infarction. In large mammals, however, results are controversial and long-term follow-up data are lacking. We thus assessed the long-term effects of high-dose erythropoietin on left ventricular infarct size and function in an ovine model of reperfused myocardial infarction. After 90 minutes of coronary occlusion followed by reperfusion, sheep received recombinant human erythropoietin (rhEPO) 3000 units/kg on 3 consecutive days (rhEPO group, n=7) or vehicle (placebo group, n=6). Ten weeks later, ventricular function was assessed by echocardiography and catheterization. Infarct size, evaluated as percent fibrotic myocardium (morphometry) and by hydroxyproline quantification, was similar in both groups (morphometry: rhEPO: 22.1 +/- 5.5%, placebo: 18.1 +/- 3.3%, P not significant; hydroxyproline: rhEPO: 6.6 +/- 1.3 microg/mg wet weight, placebo: 7.1 +/- 0.9 microg/mg, P not significant). Ventricular function was diminished in the rhEPO group, as indicated by lower septal wall thickening at the infarct border zone (rhEPO: -1.9 +/- 16.4%, placebo: 20.5 +/- 17%, P<0.04), higher end systolic volume (rhEPO: 47 +/- 14.3 mL, placebo: 32.6 +/- 7.3 mL, P<0.05), and higher end diastolic pressure (rhEPO: 17 +/- 6.5 mm Hg, placebo: 10.1 +/- 2.8 mm Hg, P<0.03). In the rhEPO group, left ventricular endocardial area was larger, suggesting dilatation. High-dose erythropoietin has no cardioprotective effects in sheep with reperfused myocardial infarction.
publishDate 2006
dc.date.none.fl_str_mv 2006-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/245050
Olea, Fernanda Daniela; Vera Janavel, Gustavo; De Lorenzi, Andrea; Cuniberti, Luis Alberto; Yannarelli, Gustavo Gabriel; et al.; High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction; Lippincott Williams; Journal of Cardiovascular Pharmacology; 47; 6; 6-2006; 736-741
0160-2446
CONICET Digital
CONICET
url http://hdl.handle.net/11336/245050
identifier_str_mv Olea, Fernanda Daniela; Vera Janavel, Gustavo; De Lorenzi, Andrea; Cuniberti, Luis Alberto; Yannarelli, Gustavo Gabriel; et al.; High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction; Lippincott Williams; Journal of Cardiovascular Pharmacology; 47; 6; 6-2006; 736-741
0160-2446
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1097/01.fjc.0000211766.59636.0d
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Lippincott Williams
publisher.none.fl_str_mv Lippincott Williams
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083223650566144
score 13.22299

Publicaciones similares